We came across one bullish thesis to DR Horton, Inc. on HaywardUCuddleme’s value investing subreddit. In this article, we will summarize the bulls’ thesis on DHI. The stock of DR Horton, Inc. it was trading at $158.46 on December 2. According to Yahoo Finance, DHI’s trailing and forward P/E were 13.60 and 13.85, respectively.

yuttana Contributor Studio/Shutterstock.com

DR Horton, Inc. operates as a homebuilder in the East, North, Southeast, South Central, Southwest, and Northwest regions of the United States and currently trades at $145 per share, well below the base case valuation of $254, implying approximately 60% upside and an expected IRR of 11.7% over the next 12-18 months. The market is treating Horton as a low-margin, late-cycle homebuilder, discounting its growth at 2.4%, net margin at 8.5% and ROE at 10.2%. In contrast, expected revenue growth of 3.5%, net margins of 12.5% ​​and ROE of 15%, creates a clear opportunity for mispricing.

Growth is supported by Horton’s controlled batch supply through its majority-owned Forestry unit, a broad national footprint and the conversion of the backlog, which should drive volumes above market expectations as cycle times normalize and affordability improves. Margins are also resilient, with 20-year low gross margins, tight overhead and integrated mortgage, title and closing services that reduce leakage, supporting a short-term net margin of 11.5% and a steady state of 12.5% ​​as incentives normalize. Return on equity benefits from scale, Forestar-backed lot changes and ongoing share buybacks, resulting in a sustainable ROE of 15%.

The peer multiples (roughly 9.5x earnings, 1.3x sales and 1.7x book) also suggest Horton is undervalued, with implied prices between $210 and $240, consistent with my $254 DCF and $231-$277 intrinsic range. Key catalysts include Q4 FY2025, Q1 FY2026 and Q2 FY2026 results that could demonstrate healthy net orders, stable gross margins, overhead discipline and ongoing purchase and repurchase expenses, supporting an intrinsic value appreciation.

Downside risks include persistent mortgage rates, ongoing incentives or constraints on Forestar’s lot supply, which could compress growth, margins and ROE, pushing fair value closer to $141-162. Conservative assumptions, including $1 billion in unfunded liabilities, further support the investment case. Overall, the combination of mispricing, operational resilience and visible catalysts make DR Horton an attractive opportunity.

We previously covered a bullish thesis to DR Horton, Inc. (DHI) from Let it Compound in May 2025, which highlighted the company’s domestic footprint, controlled lot supply through Forestar, strong returns and disciplined capital approach. The company’s stock price has appreciated approximately 26.01% since our coverage. HaywardUCuddleme shares a similar thesis, but emphasizes a mispricing opportunity, projecting higher net margins, ROE, and multiple peer revaluation benefits.